Advarra

1. Novartis Pharmaceuticals Corporation $277,956 16 payments
2. E.R. Squibb & Sons, L.L.C. $71,180 29 payments
3. Celgene Corporation $60,997 23 payments
4. Zimmer Biomet Holdings, Inc. $47,501 25 payments
5. Pfizer Inc. $34,485 15 payments
6. CSL Behring $26,580 29 payments
7. Stryker Corporation $23,255 25 payments
8. Medline Industries, Inc. $19,695 17 payments
9. CVRx, Inc. $18,130 16 payments
10. Axonics Modulation Technologies, Inc. $16,545 21 payments

1. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $112,691 1 payment
2. A Randomized, Two-Arm, Placebo-Controlled, Participant and Investigator-Blinded Study Investigating the Efficacy, Safety and Tolerability of Dfv890 in Patients With Symptomatic Knee Osteoarthritis $62,743 1 payment
3. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $56,540 22 payments
4. A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) $35,830 16 payments
5. A Phase 3 Randomized Multicenter Openlabel Crossover Study Assessing Subject Perception of Treatment Burden With Use of Weekly Growth Hormone Somatrogon Versus Daily Growth Hormone Genotropin Registered Injections in Children With Growth Hormone Deficiency $34,485 15 payments
6. A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 MG Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (Gca) $20,270 1 payment
7. A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate Or Fingolimod Therapy $19,195 1 payment
8. A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced Chronic Pain (Cicp) Following Photorefractive Keratectomy (PRK) Or Laser-Assisted in Situ Keratomileusis (Lasik) Surgeries $18,345 1 payment
9. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $18,145 18 payments
10. Artistry $16,545 21 payments

1. Other $1,700 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.